Related Experiment Videos

Review of current and emerging therapies in type 2 diabetes mellitus

Nissa Mazzola1

  • 1College of Pharmacy and Allied Health Professions, St. John's University, Queens, and North Shore University Hospital, Manhasset, NY, USA. mazzolan@stjohns.edu

The American Journal of Managed Care
|May 8, 2012
PubMed

Insights

Advances in type 2 diabetes mellitus (T2DM) treatment include prevention strategies and new glucose-lowering medications targeting various defects. Management now also focuses on comorbidities like dyslipidemia and hypertension.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) management has evolved with prevention and novel drug classes.
  • Current T2DM therapies address beta-cell failure and insulin resistance.
  • Emerging treatments target other defects like incretin deficiency.

Purpose of the Study:

  • To discuss pharmacologic agents for T2DM based on current guidelines.
  • To provide an update on the newest diabetes medications.
  • To include managed care aspects of T2DM treatment.

Main Methods:

  • Review of guidelines from the American Diabetes Association/European Association for the Study of Diabetes.
  • Analysis of relevant clinical studies on T2DM pharmacotherapies.
  • Discussion of specific drug classes, including incretin-based therapies and amylin agonists.

Main Results:

  • Newer agents targeting incretin deficiency/resistance are increasingly used.
  • Therapeutic focus now includes managing comorbidities such as dyslipidemia, hypertension, and obesity.
  • Updated information on novel drugs and managed care is presented.

Conclusions:

  • T2DM treatment incorporates prevention, traditional drugs, and newer agents targeting diverse defects.
  • Comorbidity management is a key aspect of modern T2DM pharmacotherapy.
  • This review offers an update on T2DM drug therapies and care strategies.

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...